Correlation between STK33 and the pathology and prognosis of lung cancer

Lu,Yi; Tang,Jie; Zhang,Wenmei; Shen,Ce; Xu,Ling; Yang,Danrong

doi:10.3892/ol.2017.6766

Correlation between STK33 and the pathology and prognosis of lung cancer

Authors:
- Yi Lu
- Jie Tang
- Wenmei Zhang
- Ce Shen
- Ling Xu
- Danrong Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: August 17, 2017 https://doi.org/10.3892/ol.2017.6766
Pages: 4800-4804
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Correlation between the expression of STK33 and the pathology of lung cancer was investigated, to explore its effects on prognosis. Hundred and two lung cancer patients diagnosed by pathological examinations were randomly selected in Shanghai Jiao Tong University Affiliated Sixth People's Hospital from February, 2012 to February, 2017 to serve as observation group, and the tumor tissues were collected. At the same time, 19 patients with lung benign lesions were selected and lung tissues were also collected to serve as control group. RT-qPCR was used to detect the expression of STK33 mRNA in tissues. Expression levels of STK33 protein were detected and compared by SP immunohistochemistry staining and western blot analysis. Statistical analysis was performed to analyze the correlation between STK33 expression and the pathology and prognosis of lung cancer. Results of PCR showed that expression level of STK33 gene in control group was significantly lower than that in observation group (p<0.05). The expression level of STK33 mRNA in lung adenocarcinoma and squamous cell carcinoma was lower than that in lung small cell carcinoma and large cell carcinoma (p<0.05). Western blot analysis showed that the expression level of STK33 protein in lung small cell carcinoma and large cell carcinoma was significantly higher than that in lung adenocarcinoma and squamous cell carcinoma (p<0.05). Immunohistochemistry staining showed that the positive rate of STK33 in lung large cell carcinoma (100%) and small cell carcinoma (100%) was significantly higher than that in lung adenocarcinoma (88.1%) and squamous cell carcinoma (86.2%) (p<0.05). The 5-year survival rate analysis showed that the recurrence-free survival rate and overall survival rate of STK33 gene high expression level group were significantly lower than those of low expression level group (p<0.05). The differential expression level of STK33 is related to the pathology and prognosis of lung cancer, which is of great value in clinical diagnosis and prognosis evaluation.

View Figures

View References

1	Wakeam E, Acuna SA, Leighl NB, Giuliani ME, Finlayson SRG, Varghese TK and Darling GE: Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: A propensity-matched analysis of survival. Lung Cancer. 109:78–88. 2017. View Article : Google Scholar : PubMed/NCBI
2	Lopez-Pastorini A, Riedel R, Koryllos A, Beckers F, Ludwig C and Stoelben E: The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer. Lung Cancer. 109:68–73. 2017. View Article : Google Scholar : PubMed/NCBI
3	Wu L, Leng D, Cun D, Foged C and Yang M: Advances in combination therapy of lung cancer: Rationales, delivery technologies and dosage regimens. J Control Release. 260:78–91. 2017. View Article : Google Scholar : PubMed/NCBI
4	Chen C, Huang L, Zhang G, Li Y, Li L, Bai X, Liu W, Wang H and Li J: STK33 potentiates the malignancy of hypopharyngeal squamous carcinoma: Possible relation to calcium. Cancer Biol Ther. 17:976–984. 2016. View Article : Google Scholar : PubMed/NCBI
5	Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et al: Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med. 209:697–711. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wang P, Cheng H, Wu J, Yan A and Zhang L: STK33 plays an important positive role in the development of human large cell lung cancers with variable metastatic potential. Acta Biochim Biophys Sin (Shanghai). 47:214–223. 2015. View Article : Google Scholar : PubMed/NCBI
7	Brauksiepe B, Baumgarten L, Reuss S and Schmidt ER: Co-localization of serine/threonine kinase 33 (Stk33) and vimentin in the hypothalamus. Cell Tissue Res. 355:189–199. 2014. View Article : Google Scholar : PubMed/NCBI
8	Milenic DE, Baidoo KE, Kim YS, Barkley R and Brechbiel MW: Targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody, panitumumab. Transl Oncol. 10:535–545. 2017. View Article : Google Scholar : PubMed/NCBI
9	Groner B and von Manstein V: Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 451:1–14. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhu Y, Bassoff N, Reinshagen C, Bhere D, Nowicki MO, Lawler SE, Roux J and Shah K: Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors. Sci Rep. 7:26022017. View Article : Google Scholar : PubMed/NCBI
11	Shen H, Xing C, Cui K and Li Y, Zhang J, Du R, Zhang X and Li Y: MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. Cell Death Differ. 24:1253–1262. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lim SY, Menzies AM and Rizos H: Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer. 123:(S11). 2118–2129. 2017. View Article : Google Scholar : PubMed/NCBI
13	Ye H, Shao M, Shi X, Wu L, Xu B, Qu Q and Qu J: Predictive assessment in pharmacogenetics of glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients. Sci Rep. 7:26702017. View Article : Google Scholar : PubMed/NCBI
14	Brace PT, Tezera LB, Bielecka MK, Mellows T, Garay D, Tian S, Rand L, Green J, Jogai S, Steele AJ, et al: Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathology. PLoS Pathog. 13:e10063672017. View Article : Google Scholar : PubMed/NCBI
15	Reuss S, Brauksiepe B, Disque-Kaiser U and Olivier T: Serine/threonine-kinase 33 (Stk33) - Component of the neuroendocrine network? Brain Res. 1655:152–160. 2017. View Article : Google Scholar : PubMed/NCBI
16	Huang L, Chen C, Zhang G, Ju Y, Zhang J, Wang H and Li J: STK33 overexpression in hypopharyngeal squamous cell carcinoma: Possible role in tumorigenesis. BMC Cancer. 15:132015. View Article : Google Scholar : PubMed/NCBI
17	Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 137:821–834. 2009. View Article : Google Scholar : PubMed/NCBI
18	Mujica AO, Hankeln T and Schmidt ER: A novel serine/threonine kinase gene, STK33, on human chromosome 11p15.3. Gene. 280:175–181. 2001. View Article : Google Scholar : PubMed/NCBI
19	Yang T, Song B, Zhang J, Yang GS, Zhang H, Yu WF, Wu MC, Lu JH and Shen F: STK33 promotes hepatocellular carcinoma through binding to c-Myc. Gut. 65:124–133. 2016. View Article : Google Scholar : PubMed/NCBI
20	Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ, et al: STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 71:5818–5826. 2011. View Article : Google Scholar : PubMed/NCBI